about
Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission TomographySurvival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up.The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scaleInternational validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.FDG-PET in the clinical management of Hodgkin lymphoma.Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs.FDG-PET/CT based response-adapted treatment.Early interim PET scan in Hodgkin lymphoma: where do we stand?Treatment of Hodgkin lymphoma: the past, present, and future.Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.PET imaging in lymphoma.Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma.Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies.Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma.Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-fluorodeoxyglucose / Positron Emission Tomography in advanced Hodgkin lymphoma.Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.Clinical presentation and staging of Hodgkin lymphoma.The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy.123 I-MIBG imaging for detection of anthracycline-induced cardiomyopathy.Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement.No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma.Uptake of FDG in Lemierre's syndrome with normal leucocyte scintigraphy.Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement.Cancer mortality does not differ between migrants and Danish-born patients.Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial.When and how to perform surveillance imaging in patients with lymphoma, and is it worth it?Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.PET/CT for Staging; Past, Present, and Future.Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group.International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).Prognostic value of baseline metabolic tumor volume in early stage Hodgkin's lymphoma in the standard arm of H10 trial.Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients.
P50
Q26801870-DEB93585-CB02-4E57-BC99-5FF4FA55EBCCQ31138212-CAB3DCFE-BD98-4D95-9AD3-D6A50053DB79Q33696003-73ED3FE3-F98C-4DE5-BAC5-68E01130DF1DQ34334369-357075C7-09B5-49B1-A885-E85D5F93B1C4Q34664223-51C66196-2D8C-48CE-92D5-BBB74FF980A5Q35885314-588DA7FE-DE7A-4BB8-BA21-43411DEF6C74Q36006435-9D6223B6-FE44-43CE-8D21-B4CB1C01931AQ36286595-8F87E265-146A-42AF-AD39-E4DD53E18353Q37132894-889AADF0-189C-454B-8C69-8D08F2FDA258Q37235019-4718214F-9984-4B39-9FF0-EA5C4E72580EQ37240835-A3174726-69E1-4A38-9B2F-C4CE4C298ACBQ37810092-798684D0-2FF9-483B-A735-532B50A44379Q38184954-5DBAF8CE-3CF8-4114-95A2-3C87E26B7D20Q38345572-08C2B81E-DEA1-48C8-81A1-60AE40410733Q38518999-89F73697-6178-4091-B82F-ED953CCCBB46Q38552173-617DC937-4192-4FCF-8590-8DACCFC2F04DQ38657200-E67B2EB7-8DC4-4DCD-9358-B5FA18A70477Q38741693-55003349-B149-4C6F-83F1-30AD1156A294Q38833952-A8BF2139-FF1C-4442-97A0-5A13DAF24F98Q38941888-AEE9EF7B-920A-4467-AF71-688D59416D2BQ39157770-0181E74D-8549-4B51-9C88-DC517EF48617Q39342393-B25071DF-715E-4EA2-BB0B-8C34C074B8F6Q40929122-98738E43-177C-4D4F-87D5-8833E99D5422Q41496467-9ED0110D-8554-42E0-B98D-0B5D8579192EQ43500224-F8265752-DAE3-4F13-A9DF-1AE60584D630Q44317472-D3719814-893D-45B2-8036-CE4486EB601CQ44387117-E1E415F3-0367-4C61-A2D8-98F84B38FE19Q44624532-C7CBF337-8BC1-4BC6-9A82-8BD1ED60614AQ44737313-E4A557DA-0B45-4A69-B837-F901E2401DB6Q45221374-CD0821F0-060E-4624-B917-366ED3F5C665Q45752281-E72646AA-B03D-4DC8-B094-8EEB32F6C9A1Q46531267-33CA4FAB-8AC1-434D-9ECA-D15DCB365A96Q46568257-B0E9CC16-575B-4F44-8386-47870D8AA46BQ46693607-C531900A-5EF7-4942-A232-79108F139405Q47806551-79BA0036-FA1D-498D-8405-A514E39BD659Q47884628-950F70BC-DBD2-4DA9-B6C7-2BE855B70914Q48669191-D4CEA8EA-8728-4D53-98BC-939E0F6F8131Q50044419-C68B8C6D-76D5-484D-AEC8-E8BC0832247BQ50108957-BD170897-FE3F-49BA-B0E9-C7D06931DCDBQ50231478-946E351D-A09E-4A31-8521-986691720810
P50
description
researcher ORCID ID = 0000-0003-3873-1741
@en
wetenschapper
@nl
name
Martin Hutchings
@ast
Martin Hutchings
@en
Martin Hutchings
@es
Martin Hutchings
@nl
type
label
Martin Hutchings
@ast
Martin Hutchings
@en
Martin Hutchings
@es
Martin Hutchings
@nl
prefLabel
Martin Hutchings
@ast
Martin Hutchings
@en
Martin Hutchings
@es
Martin Hutchings
@nl
P106
P108
P31
P496
0000-0003-3873-1741